Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia.

abstract：:Primary cardiac lymphoma (PCL) is a rare and usually fatal neoplasm, which may cause syncope, arrhythmia, heart failure and pericardial effusion as presenting clinical complaints. A case of PCL in a 72-year-old man with moderate aortic stenosis is presented. The patient was investigated because of pericardial effusion...

journal_title：Leukemia research

authors： Rolla G,Bertero MT,Pastena G,Tartaglia N,Corradi F,Casabona R,Motta M,Caligaris-Cappio F

更新日期：2002-01-01 00:00:00

abstract：:Information about the expression of some myelomonocytic markers in lymphocytes of patients with B-CLL is scarce. We studied the CD13, CD14, CD11c and CD68 surface antigens in 42 controls and in 38 patients with B-CLL to detect their possible reactivity. Eighty-nine percent of B-CLL expressed very strongly the CD14 ant...

journal_title：Leukemia research

authors： Woessner S,Florensa L,Besses C,Vilà RM,Gallés C,Palou L,Sabrafen JS

更新日期：1992-01-01 00:00:00

abstract：:The resistance to all trans retinoic acid (ATRA) differentiating treatment is a consequence, in most of the cases, of either increased catabolism or down regulation of ATRA uptake. Recently, we have shown that ATRA efficiency to differentiate HL-60 cells was enhanced about 30 times after its incorporation into Low Den...

journal_title：Leukemia research

authors： Gueddari N,Madoulet C,Lefebvre P,Berthou L,Chomienne C,Jardillier JC

更新日期：2000-06-01 00:00:00

abstract：:All-trans retinoic acid (ATRA) or phorbol-12-myristate-13-acetate (PMA) are two representative inducers which induce the differentiation of HL-60 cells to myelocytes and monocytes respectively. Structural modifications of the pentasaccharide core portion of N-glycans on cell surface glycoproteins during differentiatio...

journal_title：Leukemia research

authors： Li Z,Liu AH,Liu F,Chen HL

更新日期：1998-08-01 00:00:00

abstract：:Bcr-Abl tyrosine kinase inhibitor induces apoptosis and erythroid differentiation of K562 cells. During this erythroid differentiation, c-Myc and cyclin D1 transcripts are transiently downregulated. Accordingly, we studied the effect of cyclin D1 overexpression on erythroid differentiation. After treatment with 250 nM...

journal_title：Leukemia research

authors： Kawano T,Horiguchi-Yamada J,Saito S,Iwase S,Furukawa Y,Kano Y,Yamada H

更新日期：2004-06-01 00:00:00

abstract：:Our previous studies have demonstrated that a previously unrecognized role of CFTR in hematopoiesis and acute leukemia. Here, we show that CFTR inhibitor CFTR-inh172 possesses ability to inhibit human T-cell acute lymphoblastic leukemia cells. In detail, CFTR-inh172 inhibited cell proliferation, promoted apoptosis and...

journal_title：Leukemia research

authors： Liu M,Liao H,Chen Y,Lin Z,Liu Y,Zhang X,Chan HC,Sun H

更新日期：2019-11-01 00:00:00

abstract：:We describe a 79-year-old man who had massive pleural effusion and a proliferation of prolymphocytic leukemia cells in the peripheral blood, bone marrow, and pleural effusion fluid. Immunophenotyping of leukemia cells revealed either CD3+CD4+CD8-CD25+ or CD3+CD4+CD8+CD25+. The antibody against human T-cell lymphotropi...

journal_title：Leukemia research

authors： Ogasawara T,Narita C,Kawauchi K

更新日期：2007-03-01 00:00:00

abstract：:Bone marrow cells of five patients with acute myeloid leukemia were fractionated by means of counterflow centrifugation (elutriation). The different fractions were enriched with cells belonging to subsequent stages of the cell cycle. Cytokinetic evaluation of these cell fractions was performed by [3H]thymidine autorad...

journal_title：Leukemia research

authors： Vierwinden G,Drenthe-Schonk AM,Plas AM,Linssen PC,Pennings AH,Holdrinet RS,van Egmond J,Wessels JM,Haanen CA

更新日期：1982-01-01 00:00:00

abstract：:The National Comprehensive Cancer Network (NCCN) defines the following types of acute myeloid leukemia (AML) as favorable-risk: acute promyelocytic leukemia with t(15;17) (APL); AML with core-binding factor (CBF) rearrangements, including t(8;21) and inv(16) or t(16;16) without mutations in KIT (CBF-KITwt); and AML wi...

journal_title：Leukemia research

authors： Strickland SA,Shaver AC,Byrne M,Daber RD,Ferrell PB,Head DR,Mohan SR,Mosse CA,Moyo TK,Stricker TP,Vnencak-Jones C,Savona MR,Seegmiller AC

更新日期：2018-02-01 00:00:00

abstract：:A novel Philadelphia (Ph1) chromosome positive cell line, designated KYO-1, was established from the peripheral blood of a patient with chronic myelogenous leukemia (CML) in blastic crisis. Although this line had a unique capacity to differentiate spontaneously along the erythroid and monocytoid lineages as evidenced ...

journal_title：Leukemia research

authors： Ohkubo T,Kamamoto T,Kita K,Hiraoka A,Yoshida Y,Uchino H

更新日期：1985-01-01 00:00:00

abstract：:Myelodysplastic syndrome (MDS) in children has been reported to be associated with various constitutional anomalies; however, it has not been described previously in patients with Griscelli syndrome (GS). In this report, we present a case with GS and refractory anemia with an excess of blasts. We believe that careful ...

journal_title：Leukemia research

authors： Cetin M,Hiçsönmez G,Göğüş S

更新日期：1998-09-01 00:00:00

abstract：:The onset of acute myeloid leukemia following ionizing radiation or alkylating agent exposure is antedated months to years by the development of 'preleukemia', or secondary myelodysplastic syndrome (sMDS). Mitochondrial abnormalities induced by chloramphenicol and clonal deletions of mitochondrial DNA (mt DNA) in the ...

journal_title：Leukemia research

authors： Hatfill SJ,La Cock CJ,Laubscher R,Downing TG,Kirby R

更新日期：1993-11-01 00:00:00

abstract：:Mantle cell lymphoma (MCL) is an aggressive malignancy and new treatment modalities must be established to increase patient survival time. In the search for new therapeutic targets, reliable and well-characterised in vitro models are essential. In this study, we have characterised three MCL cell lines (SP53, Granta 51...

journal_title：Leukemia research

authors： Ek S,Ortega E,Borrebaeck CA

更新日期：2005-02-01 00:00:00

abstract：:Acute myeloid leukemia is an aggressive disease that arises from clonal expansion of malignant hematopoietic precursor cells of the bone marrow. Deletions on the long arm of chromosome 9 (del(9q)) are observed in 2% of acute myeloid leukemia patients. Our deletion analysis in a cohort of 31 del(9q) acute myeloid leuke...

journal_title：Leukemia research

authors： Naarmann-de Vries IS,Sackmann Y,Klein F,Ostareck-Lederer A,Ostareck DH,Jost E,Ehninger G,Brümmendorf TH,Marx G,Röllig C,Thiede C,Crysandt M

更新日期：2019-01-01 00:00:00

abstract：:Superoxide dismutase "SOD" enzyme levels in leucocytes of patients with acute and chronic leukemia, were measured by using Misra and Fridovich's epinephrine method. In all types of leukemia, the SOD levels were found to be significantly higher than normals. However, these levels decreased to normal in remission. No re...

journal_title：Leukemia research

authors： Kökoğlu E,Aktuğlu G,Belce A

更新日期：1989-01-01 00:00:00

abstract：:Dose reductions or interruptions may be required to manage treatment-associated adverse events among patients with myelodysplastic syndromes (MDS) treated with lenalidomide; such modifications are recommended to sustain therapy and maximize treatment duration. The aim of this retrospective case-control study was to de...

journal_title：Leukemia research

authors： DeZern AE,Binder G,Ni Q,McGuire M,Smith BD

更新日期：2017-12-01 00:00:00

abstract：:Although verapamil, cyclosporin A. cremophor EL and PSC-833 are active as multidrug resistance modulators, there has been limited study of these compounds as possible chemotherapy enhancing agents against drug-sensitive tumors. We compared these agents as modifiers of VP-16 cytotoxicity in vitro and modifiers of VP-16...

journal_title：Leukemia research

authors： Slater L,Sweet P,Wetzel M,Stupecky M,Osann K

更新日期：1995-08-01 00:00:00

abstract：:This prospective phase II clinical trial evaluated the effects of single-dose mitoxantrone (36 mg/m2 on day 1) in combination with continuous infusion intermediate-dose cytarabine plus etoposide in 25 patients with refractory or early relapsed acute myeloid leukemia (AML). We compared the results of our current study ...

journal_title：Leukemia research

authors： Lee SS,Lee JH,Lee JH,Kim DY,Kim SH,Lim SN,Lee YS,Seol M,Ryu SG,Kang YA,Jang S,Park CJ,Chi HS,Yun SC,Lee KH

更新日期：2009-04-01 00:00:00

abstract：:IL-3 stimulated the production of IL-6 from a bone marrow-adherent cell population, macrophages and from hemopoietic supportive stromal cell lines. It also induced IL-6 production from a stem cell-enriched population of bone marrow cells which did not produce IL-6 without stimulation. In contrast, stimulation with IL-...

journal_title：Leukemia research

authors： Miyashita M,Sugimoto K,Suzuki J,Taniguchi S,Aramaki K,Mori KJ

更新日期：1991-01-01 00:00:00

abstract：BACKGROUND:Therapy strategies for myelodysplastic syndromes (MDS) and juvenile myelomonocytic leukemia (JMML) vary considerably. OBJECTIVE:To review the treatment of Brazilian children who were diagnosed with MDS or JMML in the past decade and reported to the Brazilian Cooperative Group on Pediatric Myelodysplastic Sy...

journal_title：Leukemia research

authors： Valera ET,Latorre Mdo R,Mendes WL,Seber A,Lee ML,de Paula MJ,Loggetto SR,Velloso E,Niero-Melo L,Lopes LF,Brazilian Cooperative Group on Pediatric Myelodysplastic Syndromes.

更新日期：2004-09-01 00:00:00

abstract：:We examined the symptoms and referral rates to specialized palliative care and psychosocial oncology services of patients with acute leukemia. The Memorial Symptom Assessment Scale (MSAS) was completed by 249 adult patients with acute leukemia. Patients reported a median of 9 physical and 2 psychological symptoms, and...

journal_title：Leukemia research

authors： Zimmermann C,Yuen D,Mischitelle A,Minden MD,Brandwein JM,Schimmer A,Gagliese L,Lo C,Rydall A,Rodin G

更新日期：2013-07-01 00:00:00

abstract：:Dasatinib was approved for the treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients in first line therapy based on the demonstration of efficacy and safety reported in patients enrolled in clinical trials. We describe a multicentric Italian "real-life" experience of dasatinib used as frontline treat...

journal_title：Leukemia research

authors： Breccia M,Stagno F,Luciano L,Abruzzese E,Annunziata M,D'Adda M,Maggi A,Sgherza N,Russo-Rossi A,Pregno P,Castagnetti F,Iurlo A,Latagliata R,Cedrone M,Di Renzo N,Sorà F,Rege-Cambrin G,La Nasa G,Scortechini AR,Greco G

更新日期：2016-01-01 00:00:00

abstract：:We compared the efficacy and toxicity of BEAM (BCNU, etoposide, cytarabine and melphalan) and BuCyE (busulfan, cyclophosphamide and etoposide), given prior to autologous stem cell transplantation (ASCT), in 65 patients with non-Hodgkin's lymphoma. Of these 65 patients, 43 received BEAM and 22 received BuCyE. Their age...

journal_title：Leukemia research

authors： Kim JE,Lee DH,Yoo C,Kim S,Kim SW,Lee JS,Park CJ,Huh J,Suh C

更新日期：2011-02-01 00:00:00

abstract：:In acute lymphoblastic leukemia (ALL) patients, automated fluorescence fragment analysis (ALF) has been reported to improve the monoclonality detection rate of immunoglobulin heavy chain genes (IgH) polymerase chain reaction (PCR) analysis. This study performed complementary determining region (CDR) I and III PCR on s...

journal_title：Leukemia research

authors： Gleissner B,Maurer J,Sindram A,Reinhard R,Thiel E

更新日期：2001-09-01 00:00:00

abstract：:We evaluated outcomes in two consecutive groups of AML patients age>60 years in CR after 7+3 induction therapy. Group 1 received consolidation with cytarabine 1.5g/m(2) q12h×6+daunorubicin for two cycles, while group 2 received consolidation with 7+3 followed by mitoxantrone+etoposide. For patients with intermediate-r...

journal_title：Leukemia research

authors： Hassanein M,Atenafu EG,Schuh AC,Yee KW,Minden MD,Schimmer AD,Gupta V,Brandwein JM

更新日期：2013-05-01 00:00:00

abstract：BACKGROUND:Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders, with very different prognosis in given individuals; age and comorbidities are emerging as relevant patient-related factors influencing clinical outcome in MDS. Our aim was to evaluate the impact of age, comorbidities and disease s...

journal_title：Leukemia research

authors： Balleari E,Salvetti C,Del Corso L,Filiberti R,Bacigalupo A,Bellodi A,Beltrami G,Bergamaschi M,Berisso G,Calzamiglia T,Carella AM,Cavalleri M,Da Col A,Favorini S,Forni GL,Goretti R,Miglino M,Mitscheuning L,Molinari E,

更新日期：2015-08-01 00:00:00

abstract：:As sensitization of leukemia cells with granulocyte colony-stimulating factor (G-CSF) can enhance the cytotoxicity of chemotherapy in myeloid malignancies, a pilot study was conducted in order to evaluate the effect of G-CSF priming combined with low-dose chemotherapy in patients with higher risk myelodysplastic syndr...

journal_title：Leukemia research

authors： Wang FX,Zhang WG,He AL,Cao XM,Chen YX,Zhao WH,Yang Y,Wang JL,Zhang PY,Gu LF

更新日期：2016-09-01 00:00:00

abstract：:GNAS1 gene is located at the long arm of chromosome 20 (q13.32). GNAS1 gene deletion has never been investigated in MDS. A GNAS1 activating mutation (R201) was recently found in MDS. We applied FISH and DHPLC plus sequencing to investigate GNAS1 gene in MDS cases with and without del(20q) at karyotype. ...

journal_title：Leukemia research

authors： Di Giacomo D,Lema Fernandez AG,Pierini T,Crescenzi B,Brandimarte L,Matteucci C,Testoni N,Mecucci C

更新日期：2014-07-01 00:00:00

abstract：:During monocyte-macrophage differentiation of HL-60 cells by 12-O-tetradecanoyl phorbol 13-acetate, the intracellular globular(G)-actin and polymerized(F)-actin increased 3-fold and 1.7-fold, respectively. Time course studies showed that these changes of actin levels were nearly coincident with the development of macr...

journal_title：Leukemia research

authors： Uemura Y,Nishikawa M,Komada F,Shirakawa S

更新日期：1989-01-01 00:00:00

abstract：:This retrospective study of the thrombocythemia Italian registry (RIT) documented that 71 (30.6%) out of 232 ET patients experienced 88 cardiovascular adverse events (CV-AEs) during anagrelide treatment (522 pt-y). The rate of CV-AEs was: 24.1% for palpitations, 4.3% for angina, 3.5% for arterial hypertension, 3.0% fo...

journal_title：Leukemia research

authors： Gugliotta L,Tieghi A,Tortorella G,Scalzulli PR,Ciancia R,Lunghi M,Cacciola E,Cacciola R,Candoni A,Crugnola M,Codeluppi K,Usala E,Specchia G,Martinelli V,Palmieri F,Pierri I,Liberati AM,Iurlo A,Grossi A,Vannucchi AM

更新日期：2011-12-01 00:00:00